Jefferies Starts Mirati Therapeutics (MRTX) at Buy

December 18, 2013 6:39 AM EST
Get Alerts MRTX Hot Sheet
Price: $5.50 +0.92%

Rating Summary:
    5 Buy, 4 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade MRTX Now!
Join SI Premium – FREE
Jefferies initiates coverage on Mirati Therapeutics (NASDAQ: MRTX) with a Buy. PT $36.00.

Analyst Thomas Wei weighs in: "Mirati has two small-molecule oncology drugs that target niche, but potentially lucrative populations. MGCD265 inhibits MET, AXL, and VEGF, and we like the company’s strategy to target a niche of lung cancer patients with MET/AXL mutations/alterations (8-10% of NSCLC). We also see a high probability that Phase 3 asset mocetinostat will have positive data in MDS on a response rate endpoint."

For an analyst ratings summary and ratings history on Mirati Therapeutics click here. For more ratings news on Mirati Therapeutics click here.

Shares of Mirati Therapeutics closed at $16.64 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage

Related Entities

Jefferies & Co, Thomas Wei

Add Your Comment